TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines

Tuberculosis

Volumn 99, Issue , 2016, Pages S8-S11

  Kaufmann, Stefan H E ^a   Fortune, Sarah ^b   Pepponi, Ilaria ^c,d   Ruhwald, Morten ^e   Schrager, Lewis K ^f   Ottenhoff, Tom H M ^g,h  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d VETERINARY LABORATORIES AGENCY   (United Kingdom)

^e STATENS SERUM INSTITUT   (Denmark)

^f AERAS   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h TuBerculosis Vaccine Initiative (TBVI)   (Netherlands)

Author keywords

Biomarker; Cattle tuberculosis; Global gene expression; Human challenge; Immunodiagnosis; Vaccine

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; HLA E ANTIGEN; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; RECOMBINANT VACCINE;

ARTICLE; BOVINE MODEL; BOVINE TUBERCULOSIS; DISEASE COURSE; DRUG EFFICACY; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; TUBERCULOSIS; ANIMAL; BOVINE; CELLULAR IMMUNITY; DISEASE MODEL; DOWN REGULATION; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; METABOLISM; PROCEDURES; TUBERCULOSIS, BOVINE;

ANIMALS; BCG VACCINE; BIOMARKERS; CATTLE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; GENOME-WIDE ASSOCIATION STUDY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC TESTS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, BOVINE; VACCINES, SYNTHETIC;

EID: 84984598894     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.05.010     Document Type: Article

References (17)

1. [1] Andersen, P., Kaufmann, S.H., Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med, 4, 2014, a018523, 10.1101/cshperspect.a018523.
2. [2] Tameris, M.D., Hatherill, M., Landry, B.S., Scriba, T.J., Snowden, M.A., Lockhart, S., Shea, J.E., McClain, J.B., Hussey, G.D., Hanekom, W.A., Mahomed, H., McShane, H., MVA85A 020 Trial Study Team, Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381 (2013), 1021–1028, 10.1016/S0140-6736(13)60177-4.
3. [3] Ndiaye, B.P., Thienemann, F., Ota, M., Landry, B.S., Camara, M., Dieye, S., Dieye, N.T., Esmail, H., Goliath, R., Huygen, K., January, V., Ndiaye, I., Oni, T., Raine, M., Romano, M., Satti, I., Sutton, S., Thiam, A., Wilkinson, K.A., Mboup, S., Wilkinson, R.J., McShane, H., For the MVA85A 030 trial investigators, Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 3:3 (2015 Mar), 190–200, 10.1016/S2213-2600(15)00037-5.
4. [4] Kaufmann, S.H., Evans, T.G., Hanekom, W.A., Tuberculosis vaccines: time for a global strategy. Sci Transl Med, 7, 2015, 276fs8, 10.1126/scitranslmed.aaa4730.
5. [5] Kaufmann, S.H., McElrath, M.J., Lewis, D.J., Del Giudice, G., Challenges and responses in human vaccine development. Curr Opin Immunol 28 (2014), 18–26, 10.1016/j.coi.2014.01.009.
6. [6] Maertzdorf, J., Weiner, J. III, Kaufmann, S.H., Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis 16 (2012), 1140–1148, 10.5588/ijtld.12.0246.
7. [7] Visser, D.H., Solomons, R.S., Ronacher, K., van Well, G.T., Heymans, M.W., Walzl, G., Chegou, N.N., Schoeman, J.F., van Furth, A.M., Host immune response to tuberculous meningitis. Clin Infect Dis 60 (2015), 177–187, 10.1093/cid/ciu781.
8. [8] Deng, J., Bi, L., Zhou, L., Guo, S.J., Fleming, J., Jiang, H.W., Zhou, Y., Gu, J., Zhong, Q., Wang, Z.X., Liu, Z., Deng, R.P., Gao, J., Chen, T., Li, W., Wang, J.F., Wang, X., Li, H., Ge, F., Zhu, G., Zhang, H.N., Gu, J., Wu, F.L., Zhang, Z., Wang, D., Hang, H., Li, Y., Cheng, L., He, X., Tao, S.C., Zhang, X.E., Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity. Cell Rep 9 (2014), 2317–2329, 10.1016/j.celrep.2014.11.023.
9. [9] Hawkridge, A., Hatherill, M., Little, F., Goetz, M.A., Barker, L., Mahomed, H., Sadoff, J., Hanekom, W., Geiter, L., Hussey, G., The South African BCG trial team, Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ, 337, 2008, a2052, 10.1136/bmj.a2052.
10. [10] Joosten, S.A., van Meijgaarden, K.E., van Weeren, P.C., Kazi, F., Geluk, A., Savage, N.D., Drijfhout, J.W., Flower, D.R., Hanekom, W.A., Klein, M.R., Ottenhoff, T.H., Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog, 6, 2010, e1000782, 10.1371/journal.ppat.1000782.
11. [11] van Meijgaarden, K.E., Haks, M.C., Caccamo, N., Dieli, F., Ottenhoff, T.H., Joosten, S.A., Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathog, 11, 2015, e1004671, 10.1371/journal.ppat.1004671.
12. [12] Caccamo, N., Pietra, G., Sullivan, L.C., Brooks, A.G., Prezzemolo, T., La Manna, M.P., Di Liberto, D., Joosten, S.A., van Meijgaarden, K.E., Di Carlo, P., Titone, L., Moretta, L., Mingari, M.C., Ottenhoff, T.H., Dieli, F., Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines. Eur J Immunol 45 (2015), 1069–1081, 10.1002/eji.201445193.
13. [13] Vordermeier, H.M., Villarreal-Ramos, B., Cockle, P.J., McAulay, M., Rhodes, S.G., Thacker, T., Gilbert, S.C., McShane, H., Hill, A.V., Xing, Z., Hewinson, R.G., Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77 (2009), 3364–3373, 10.1128/IAI.00287-09.
14. [14] Dean, G., Whelan, A., Clifford, D., Salguero, F.J., Xing, Z., Gilbert, S., McShane, H., Hewinson, R.G., Vordermeier, M., Villarreal-Ramos, B., Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32 (2014), 1304–1310, 10.1016/j.vaccine.2013.11.045.
15. [15] Thom, M.L., McAulay, M., Vordermeier, H.M., Clifford, D., Hewinson, R.G., Villarreal-Ramos, B., Hope, J.C., Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months. Clin Vaccine Immunol 19 (2012), 1254–1260, 10.1128/CVI.00301-12.
16. [16] Bhuju, S., Aranday-Cortes, E., Villarreal-Ramos, B., Xing, Z., Singh, M., Vordermeier, H.M., Global gene transcriptome analysis in vaccinated cattle revealed a dominant role of IL-22 for protection against bovine tuberculosis. PLoS Pathog, 8, 2012, e1003077, 10.1371/journal.ppat.1003077.
17. [17] Hill, A.V., Vaccines against malaria. Philos Trans R Soc Lond B 366 (2011), 2806–2814, 10.1098/rstb.2011.0091.